Gammabody® Platform

LAVA’s GAMMABODY® Platform

directly induces potent killing of tumor cells

via its unique targeting of Vγ9Vδ2 (Vgamma9 Vdelta2) T cells and tumor-associated antigens (TAAs).

Bispecific VHH

  • Gammabody® platform approach is fully modular, allowing for usage of Fc and existing antibodies
  • “Off the shelf” manufacturing

They combine a variety of traits to accomplish this including:

  • High potency with EC50s in low picomolar range
  • Potential for expansion of activated Vγ9Vδ2 (Vgamma9 Vdelta2) T cells
  • Avoids the detrimental co-activation of immune-suppressive cells, such as Tregs
  • Secretion of pro-inflammatory cytokines that attract and activate other cells within the immune system
  • Antigen-presenting capability, potentially triggering an adaptive immune reaction, enabling deep and durable responses
LAVA’s Gammabody® platform acts through multiple mechanisms to induce selective, potent killing of tumor cells
LAVA’s Gammabody® platform acts through multiple mechanisms to induce selective, potent killing of tumor cells

Proof-of-principle of LAVA’s Gammabody® platform approach has been established by in vitro, in vivo and ex vivo studies which demonstrate potent cell death in both tumor cell lines and patient-derived cells in both solid tumors and hematologic malignancies. Based on this data, LAVA has advanced its lead Gammabody® platform drug candidates, LAVA-051 and LAVA-1207, into clinical development.